Provisional Codes Now Available to Report Pfizer COVID-19 Vaccine For Young Children

Provisional Codes Now Available to Report Pfizer COVID-19 Vaccine for Young Children

In anticipation of an Emergency Use Authorization (EUA) from the FDA, AMA has released provisional codes for the pediatric COVID-19 Pfizer vaccine for children aged 6 months up to 5 years of age. The administration codes for the first and second doses are also available. No decision has yet been made regarding a third dose for this age group.

In a statement accompanying the announcement of the new codes, AMA President Gerald Harmon, M.D., noted: “The AMA supports the goal of extending COVID-19 vaccination protection to a broader age range of children, because it has proven highly effective at preventing illness and death. We strongly urge all parents to get their infants and toddlers vaccinated as soon as they are eligible for a COVID-19 vaccine.”

With the addition of the three new codes, the COVID-19 vaccine codes now number 32. This includes codes for both vaccine products and administration. Appendix Q has been updated to include these codes.

The table in the appendix links the vaccine product codes to the accompanying immunization administration codes. The table includes information on the manufacturer, vaccine name, National Drug Code, and dosing information.

The provisional codes will be available for use as soon as an EUA is issued by the FDA. Information about the codes in advance will allow for a smooth transition to their use when appropriate.

How to Code Pfizer COVID-19 Vaccine for Children

Here are the descriptions of the three codes, one for the product and two for the administration of the first and second dose:

• 91308: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
• 0081A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
• 0082A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

Vaccine and administration codes for pediatric patients aged 5-11 have been released by AMA. Read about those codes here. Additional information on how to code COVID-19 treatments, vaccines, infections and more is available in the YES COVID-19 Resource Center.